Results 71 to 80 of about 536 (130)
Liver International, Volume 44, Issue 5, Page 1075-1092, May 2024.Abstract Background and Aims The beneficial effect of Hepatitis C virus (HCV) eradication by direct antiviral agents (DAAs) on liver fibrosis is well defined. Despite this, the impact of viral eradication in both hepatic and extra‐hepatic metabolic features is underreached.
Annalisa Cespiati +6 more
wiley +1 more source
Structural Analysis of Asunaprevir Resistance in HCV NS3/4A Protease
, 2015 Asunaprevir (ASV), an isoquinoline-based competitive inhibitor targeting the hepatitis C virus (HCV) NS3/4A protease, is very potent in vivo. However, the potency is significantly compromised by the drug resistance mutations R155K and D168A.
Celia A. Schiffer (148545) +2 more
core +1 more source
Small‐Molecule Regulators for Gene Switches to Program Mammalian Cell Behaviour
ChemBioChem, Volume 25, Issue 6, March 15, 2024.Small molecules have been widely utilized within the synthetic biology community as trigger input for regulating implemented genetic circuit in engineered mammalian cells. Here, we described the most commonly used small molecules and their associated genetic switches, employed to program cell behaviors, particularly within a cell and gene therapy ...
Maysam Mansouri, Martin Fussenegger
wiley +1 more source
Non-SVR rate of DAA therapy by treatment regimen received.
, 2019 SOF, sofosbuvir; SOF/LDV, sofosbuvir plus ledipasvir; 3D, ritonavir-boosted paritaprevir, plus ombitasvir and dasabuvir; GZR/EBR, grazoprevir plus elbasvir; DCV, daclatasvir; ASV, Asunaprevir;
Yi-Hao Yen (837269) +6 more
core +1 more source
Acta Pharmaceutica Sinica B, 2016 Unlike human immunodeficiency virus (HIV) and hepatitis B virus (HBV), hepatitis C virus (HCV) infection is a curable disease. Current direct antiviral agent (DAA) targets are focused on HCV NS3/4A protein (protease), NS5B protein (polymerase) and NS5A ...
Xingquan Zhang
doaj +1 more source
Mixed HCV Infection of Genotype 1B and Other Genotypes Influences Non-response during Daclatasvir + Asunaprevir Combination Therapy [PDF]
, 2018 Daclatasvir (DCV) + asunaprevir (ASV) combination therapy has become available for patients with hepatitis C virus (HCV) serogroup 1 infection. We studied the efficacy of this therapy by focusing on the factors associated with sustained virological ...
Sakaguchi, Kosaku +20 more
core +1 more source
BMC Nephrology, 2017 Background Direct-acting antivirals (DAAs) dramatically improve the treatment of hepatitis C virus (HCV) infections. However, the effects of DAAs on extra-hepatic manifestations such as HCV-associated glomerulonephritis, especially in cases with renal ...
Michiko Shimada +7 more
doaj +1 more source
Gut and Liver, 2018 Background/AimsChanges in lipid profiles in patients infected with hepatitis C virus (HCV) during direct-acting antiviral therapy have been reported in recent years.
Takeshi Chida +10 more
doaj +1 more source
, 2018 Daclatasvir, asunaprevir, and beclabuvir are direct-acting antivirals for patients with hepatitis C virus genotype 1 infection. This systematic review and meta-analysis investigating the efficacy and safety of this three-drug combination in HCV genotype ...
Duy Hieu Truong (3338097)
core +1 more source
Modulation of chimeric antigen receptor surface expression by a small molecule switch
BMC Biotechnology, 2019 Background Engineered therapeutic cells have attracted a great deal of interest due to their potential applications in treating a wide range of diseases, including cancer and autoimmunity.
Alexandre Juillerat +8 more
doaj +1 more source